Evommune, Inc. (EVMN)
20.82
+0.33
(+1.61%)
USD |
NYSE |
Jun 11, 14:44
Evommune Total Assets (Quarterly) : 322.46M for March 31, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 322.46M |
| December 31, 2025 | 224.95M |
| September 30, 2025 | 84.54M |
| Date | Value |
|---|---|
| June 30, 2025 | 96.21M |
| March 31, 2025 | 56.02M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Apogee Therapeutics, Inc. | 1.294B |
| Kymera Therapeutics, Inc. | 1.669B |
| Mineralys Therapeutics, Inc. | 652.86M |
| GRAIL, Inc. | 2.803B |
| MapLight Therapeutics, Inc. | 418.79M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 17.90M |
| Shareholders Equity (Quarterly) | 304.56M |
| Debt to Equity Ratio | 0.0299 |
| Current Ratio | 20.36 |
| Net Debt Paydown Yield | -0.22% |